Reply on Aromatase Inhibition in Advanced Breast Cancer
Author Information
Author(s): R Sainsbury
Primary Institution: Royal Free and University College Medical School
Conclusion
The evidence suggests that small differences in estrogen suppression between third-generation aromatase inhibitors do not lead to clinically significant differences in overall efficacy.
Supporting Evidence
- The only significant difference observed was in the objective response rate between letrozole and anastrozole.
- The trial showed no significant difference in overall survival between letrozole and tamoxifen.
- Anastrozole was associated with a higher incidence of fractures compared to tamoxifen.
Takeaway
This study looks at two drugs for breast cancer and finds that even if one works a little better, it doesn't really change how well patients do overall.
Methodology
The study involved a review of clinical efficacy data and comparisons from randomized trials.
Potential Biases
The open-label nature of the trials may introduce bias, particularly regarding subjective endpoints.
Limitations
The study is based on available evidence and lacks direct comparisons from large randomized trials.
Participant Demographics
Participants included postmenopausal women with advanced breast cancer, with a focus on those with hormone receptor-positive tumors.
Statistical Information
P-Value
P=0.013
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website